459 related articles for article (PubMed ID: 34497295)
1. Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Kang J; Song JW
Sci Rep; 2021 Sep; 11(1):17824. PubMed ID: 34497295
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
[TBL] [Abstract][Full Text] [Related]
4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
6. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
[TBL] [Abstract][Full Text] [Related]
7. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
8. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis.
Kang J; Han M; Song JW
Sci Rep; 2020 Sep; 10(1):15620. PubMed ID: 32973215
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
12. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton C; Chaudhuri N
Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
[TBL] [Abstract][Full Text] [Related]
13. A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
Bi Y; Rekić D; Paterniti MO; Chen J; Marathe A; Chowdhury BA; Karimi-Shah BA; Wang Y
J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):55-67. PubMed ID: 32949322
[TBL] [Abstract][Full Text] [Related]
14. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
15. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
Behr J; Kolb M; Song JW; Luppi F; Schinzel B; Stowasser S; Quaresma M; Martinez FJ
Am J Respir Crit Care Med; 2019 Dec; 200(12):1505-1512. PubMed ID: 31365829
[No Abstract] [Full Text] [Related]
17. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Oishi K; Hirano T; Murata Y; Hamada K; Uehara S; Suetake R; Yamaji Y; Asami-Noyama M; Edakuni N; Ohata S; Utsunomiya T; Sakamoto K; Onoda H; Matsumoto T; Matsunaga K; Yano M
Ther Adv Respir Dis; 2019; 13():1753466619872890. PubMed ID: 31476961
[TBL] [Abstract][Full Text] [Related]
18. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]